Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 796 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Rapid Genetic Test Could Help Guide Brain Cancer Surgery May 8, 2025 Foodie Friday: Watermelon Fruit Pizza September 3, 2021 FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Recurrent or Metastatic... September 23, 2021 Color-Blind Groom Sees Color For First Time After Bride Surprises Him... November 9, 2021 Load more HOT NEWS FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL Copanlisib Shows Promising Clinical Activity in Select Tumours with PIK3CA Mutation... Mom with Breast Cancer Who Had A Year to Live Goes... During No-Visitor Policy at Hospital, Surgeon Comforts Breast Cancer Patient Getting...
